An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Kidney International

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ki.2011.102PMID 21508925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Macrophages, inflammation, and insulin resistance.

  2010cited by this paper
• Excerpts from the US Renal Data System 2009 Annual Data Report.

  2010cited by this paper
• Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.

  2010cited by this paper
• Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes.

  2010cited by this paper
• Cardiovascular , Pulmonary and Renal Pathology Late Onset of Ccl 2 Blockade with the Spiegelmer mNOX-E 36 – 3 PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db / db Mice

  2010cited by this paper
• Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes

  2009cited by this paper
• Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll‐like receptor 2 at the glomerular filtration barrier

  2009cited by this paper
• Viral RNA and DNA trigger common antiviral responses in mesangial cells.

  2009cited by this paper
• Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis.

  2009cited by this paper
• Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif.

  2009cited by this paper
• Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice

  2009cited by this paper
• Recent developments in CCR2 antagonists

  2009cited by this paper
• Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of Cyclophosphamide to Control Diffuse Proliferative Lupus Nephritis and Pneumonitis in MRL-Fas(lpr) Mice

  2009cited by this paper
• Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.

  2008cited by this paper
• MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.

  2008cited by this paper
• Inhibition of CCR2 Ameliorates Insulin Resistance and Hepatic Steatosis in db/db Mice

  2008cited by this paper
• From Fibrosis to Sclerosis

  2008cited by this paper
• Macrophage diversity in renal injury and repair.

  2008cited by this paper
• Role of CC Chemokine Receptor 2 in Bone Marrow Cells in the Recruitment of Macrophages into Obese Adipose Tissue*

  2008cited by this paper
• The pathogenesis of diabetic nephropathy

  2008cited by this paper
• Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice

  2007cited by this paper
• New insights into structural patterns encountered in glomerulosclerosis

  2007cited by this paper
• The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice.

  2007cited by this paper
• Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease.

  2007cited by this paper
• Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy.

  2007cited by this paper
• Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

  2007cited by this paper
• Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients.

  2006cited by this paper
• Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.

  2006cited by this paper
• The role of inflammation as a pathogenic factor in the development of renal disease in diabetes

  2005cited by this paper
• Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease.

  2005cited by this paper
• Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions.

  2005cited by this paper
• Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.

  2004cited by this paper
• The chemokine system in diverse forms of macrophage activation and polarization.

  2004cited by this paper
• Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator.

  2004cited by this paper
• Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator

  2004cited by this paper
• CC Chemokine Ligand 5/RANTES Chemokine Antagonists Aggravate Glomerulonephritis Despite Reduction of Glomerular Leukocyte Infiltration1

  2003cited by this paper
• Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes.

  2003cited by this paper
• Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS).

  2003cited by this paper
• Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy.

  2003cited by this paper
• Podocyte number in normotensive type 1 diabetic patients with albuminuria.

  2002cited by this paper
• Urinary levels of monocyte chemoattractant protein‐1 (MCP‐1) and interleukin‐8 (IL‐8), and renal injuries in patients with type 2 diabetic nephropathy

  2002cited by this paper
• Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells*

  2002cited by this paper
• CCR2: from cloning to the creation of knockout mice.

  1999cited by this paper
• A High Glucose Concentration Stimulates the Expression of Monocyte Chemotactic Peptide 1 in Human Mesangial Cells

  1998cited by this paper
• Chemokines and leukocyte traffic

  1998cited by this paper
• Podocyte loss and progressive glomerular injury in type II diabetes.

  1997cited by this paper
• The role of macrophages in diabetic glomerulosclerosis.

  1993cited by this paper
• The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis.

  1991cited by this paper

• Targeting the CCL2/CCR2 Axis in Colorectal Cancer; Immunopharmacological Perspectives and Therapeutic Strategies.

  2025cites this paper
• CD163 and TYROBP Are Two Therapeutic Targets for Hyperglycemia‐Induced Mesangial Cell Stress

  2025cites this paper
• Tráfico leucocitario: mecanismos e impacto clínico

  2025cites this paper
• Multi-targeted pharmacological properties of cinnamyl piperazine derivatives: a comprehensive review

  2024cites this paper
• Fiery Connections: Macrophage-Mediated Inflammation, the Journey from Obesity to Type 2 Diabetes Mellitus and Diabetic Kidney Disease

  2024cites this paper
• Identification of immune-associated biomarkers of diabetes nephropathy tubulointerstitial injury based on machine learning: a bioinformatics multi-chip integrated analysis

  2024cites this paper
• The Mechanisms Underlying Chinese Medicines to Treat Inflammation in Diabetic Kidney Disease.

  2024cites this paper
• Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease

  2024cites this paper
• Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics

  2024cites this paper
• The importance of proinflammatory failed-repair tubular epithelia as a predictor of diabetic kidney disease progression

  2024cites this paper
• Role of novel biomarker monocyte chemo-attractant protein-1 in early diagnosis & predicting progression of diabetic kidney disease: A comprehensive review.

  2024cites this paper
• Depletion of CUL4B in macrophages ameliorates diabetic kidney disease via miR-194-5p/ITGA9 axis.

  2023cites this paper
• Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

  2023cites this paper
• Identification of a novel immune landscape signature as effective diagnostic markers related to immune cell infiltration in diabetic nephropathy

  2023cites this paper
• Immunological Approaches in the Treatment of Diabetic Nephropathy.

  2023cites this paper
• The Pathophysiological Role of Thymosin β4 in the Kidney Glomerulus

  2023cites this paper
• The Increase in Circulating Levels of Pro-Inflammatory Chemokines, Cytokines, and Complement C5 in Canines with Impaired Kidney Function

  2022cites this paper
• Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications

  2022cites this paper
• Macrophages in the kidney in health, injury and repair.

  2022cites this paper
• Mechanisms of podocyte injury and implications for diabetic nephropathy

  2022cites this paper
• Chronic kidney disease mediates cardiac dysfunction associated with increased resident cardiac macrophages

  2022cites this paper
• Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease-From Bench to Bedside.

  2021cites this paper
• Mitochondria in Diabetic Kidney Disease

  2021cites this paper
• Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

  2021cites this paper
• Effects of a CCR2 antagonist on macrophages and Toll-like receptor 9 expression in a mouse model of diabetic nephropathy.

  2021cites this paper
• Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy

  2021cites this paper
• Therapeutic Potential of Pro-Resolving Mediators in Diabetic Kidney Disease.

  2021cites this paper
• The Effects of M1/M2 Macrophages on the mRNA Expression Profile of Diabetic Glomerular Endothelial Cells

  2021cites this paper
• Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin.

  2020cites this paper
• The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy

  2020cites this paper
• Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis

  2020cites this paper
• Tailor-Made Amino Acids and Fluorinated Motifs as Prominent Traits in the Modern Pharmaceuticals.

  2020cites this paper
• Inflammatory Targets in Diabetic Nephropathy

  2020cites this paper
• Molecular basis of kidney disease

  2020cites this paper
• SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, 'diabetic nephropathy', IgA nephropathy and podocytopathies with FSGS lesions.

  2020cites this paper
• Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease

  2020influential citation
• Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

  2020cites this paper
• Inhibition of Bruton's TK regulates macrophage NF‐κB and NLRP3 inflammasome activation in metabolic inflammation

  2020cites this paper
• Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in Nos3 deficient mice.

  2019influential citation
• Mapping the intracellular molecular mechanisms of chemokine signalling within cancer

  2019cites this paper
• CCR2 knockout ameliorates obesity-induced kidney injury through inhibiting oxidative stress and ER stress

  2019cites this paper
• Breaking down chronic inflammatory diseases: the role of biglycan in promoting a switch between inflammation and autophagy

  2019cites this paper
• Immune effector monocyte–neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer

  2019cites this paper
• Inhibition of Bruton’s tyrosine kinase reduces NF-kB and NLRP3 inflammasome activity preventing insulin resistance and microvascular disease

  2019cites this paper
• Cilia‐localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney

  2018cites this paper
• Role of the Immune System in Diabetic Kidney Disease

  2018cites this paper
• CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease

  2018cites this paper
• Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

  2018cites this paper
• C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis.

  2018cites this paper
• The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’—implications for pre-clinical research and drug testing

  2018influential citation
• Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

  2018cites this paper
• Modulation of the renal homeostatic milieu by mononuclear phagocytes in diabetic nephropathy

  2017cites this paper
• CXCL8 Antagonist Improves Diabetic Nephropathy in Male Mice With Diabetes and Attenuates High Glucose–Induced Mesangial Injury

  2017cites this paper
• Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.

  2017cites this paper
• Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.

  2017cites this paper
• Inflammation and Inflammatory Mediators in Kidney Disease Inhibition of T-cell activation by the CTLA 4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease

  2017cites this paper
• Reprint of "Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis".

  2017cites this paper
• Evolutionary trade-offs in kidney injury and repair.

  2017cites this paper
• 8 Immunoinflammation in Diabetic Nephropathy : Molecular Mechanisms and Therapeutic Options

  2017influential citation
• DRUGS FOR DIABETIC NEPHROPATHY- FULL REVIEW

  2017influential citation
• Monocyte-Derived Dendritic Cells Impair Early Graft Function following Allogeneic Islet Transplantation

  2017cites this paper
• Novel avenues for treating diabetic nephropathy: new investigational drugs

  2017cites this paper
• Preview : Published ahead of advance online publication Macrophage polarization and function : New prospects for fibrotic disease

  2017cites this paper
• Macrophage polarization and function: new prospects for fibrotic disease

  2017cites this paper
• Diabetic nephropathy - is this an immune disorder?

  2017cites this paper
• CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells

  2016cites this paper
• Le récepteur à domaine discoïdine de type 1 : un acteur majeur des pathologies rénales chroniques et aiguës

  2016cites this paper
• C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria

  2016cites this paper
• Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology

  2016cites this paper
• Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis.

  2016cites this paper
• The chemokine (C-C motif) ligand protein synthesis inhibitor bindarit prevents cytoskeletal rearrangement and contraction of human mesangial cells.

  2016cites this paper
• Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy

  2016cites this paper
• Targeting inflammation in diabetic kidney disease: early clinical trials

  2016cites this paper
• Role of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension

  2015cites this paper
• Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade

  2015cites this paper
• Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.

  2015cites this paper
• Twenty years after ACEIs and ARBs : Emerging Treatment Strategies 1 for Diabetic Nephropathy 2 3

  2015cites this paper
• Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment

  2015cites this paper
• Standard and novel therapeutic approaches to diabetic nephropathy

  2015cites this paper
• Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

  2015cites this paper
• A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages?

  2015cites this paper
• CX3CL1–CX3CR1 Interaction Increases the Population of Ly6C−CX3CR1hi Macrophages Contributing to Unilateral Ureteral Obstruction–Induced Fibrosis

  2015cites this paper
• Diabetic nephropathy: What does the future hold?

  2015cites this paper
• Renal Protection by Genetic Deletion of the Atypical Chemokine Receptor ACKR2 in Diabetic OVE Mice

  2015cites this paper
• CCR1 and CCR2 antagonists.

  2014cites this paper
• Emerging roles of hematopoietic cells in the pathobiology of diabetic complications.

  2014cites this paper
• Treatment of albuminuria due to diabetic nephropathy: recent trial results

  2014cites this paper
• Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options

  2014cites this paper
• Therapeutic approaches to diabetic nephropathy—beyond the RAS

  2014cites this paper
• Monocytes in Sterile Inflammation: Recruitment and Functional Consequences

  2014cites this paper
• Toll-like receptors: sensing and reacting to diabetic injury in the kidney.

  2014cites this paper
• Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment

  2014cites this paper
• Novel effective drugs for diabetic kidney disease? or not?

  2014cites this paper
• Low Protein Diet Inhibits Uric Acid Synthesis and Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats

  2014cites this paper
• Molecular mechanisms of diabetic kidney disease.

  2014cites this paper
• An update on the pathomechanisms and future therapies of Alport syndrome

  2013cites this paper
• Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.

  2013influential citation
• Inflammation and the pathogenesis of diabetic nephropathy.

  2013cites this paper
• Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 – 2012

  2013cites this paper
• Changes in macrophage phenotype as the immune response evolves.

  2013cites this paper